216.73.216.38
dgid:
enl:
npi:0
/nas/content/live/oph360live/wp-content/themes/rd360/archive.php
-Advertisement-
Home Promising results for CyclAGel in treating moderate-to-severe dry eye disease

Ocular Surface Disease

Take a deep dive into the first treatment for macular telangiectasia type 2: an allogeneic encapsulated cell therapy

Watch Now
By rd360stg
Topical insulin eye drops show promise for treating ocular surface diseases
By rd360stg
Learn about a drop to treat acute infectious conjunctivitis
By rd360stg
Pain from diagnostic eye drops may signal dry eye severity
By rd360stg
Cyclosporine 0.09% can quickly improve ocular surface health in dry eye patients
By rd360stg
Treating dry eye disease: Demodex blepharitis and other considerations
By rd360stg
Real-world study finds iStent infinite lowers IOP and reduces the need for topical medication in patients with glaucoma
By rd360stg
Lotilaner improves meibomian gland function and patient-reported symptoms
By rd360stg
Phase 4 study shows that switching cyclosporine formulations can improve patient outcomes
By rd360stg
How Nerves Unite the Complex System Behind Every Healthy Tear
By rd360stg
Eyelid pressure patching enhances amniotic membrane therapy for corneal healing
By rd360stg
Spotlight on CEQUA®
By rd360stg
Dispelling eye health myths seen on social media
-Advertisement-
-Advertisement-

Contact Info

Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809

+908-505-8899
[email protected]

Social Links

© 2025 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved
-Advertisement-
-Advertisement-